Expert consensus on systemic therapy for plaque psoriasis with limited skin involvement in JAPAN: Results from a DELPHI study.
Delphi technique
Japan
consensus
dermatologic agents
psoriasis
Journal
The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545
Informations de publication
Date de publication:
04 Sep 2024
04 Sep 2024
Historique:
revised:
12
08
2024
received:
11
07
2024
accepted:
14
08
2024
medline:
4
9
2024
pubmed:
4
9
2024
entrez:
4
9
2024
Statut:
aheadofprint
Résumé
Our objective was to establish consensus on (1) which patients with plaque psoriasis and limited skin involvement (body surface area [BSA] <10%) are suitable for systemic treatment, and (2) a definition of 'topical therapy failure'. A steering committee refined 13 statements drawn from literature related to the study objectives. An independent panel of 45 clinical experts from Japan indicated their agreement to each statement using a 10-point Likert scale (Round 1; strong consensus, ≥70% of responses = 7-10 and median value ≥8). The steering committee reviewed Round 1 results and refined the statements for Round 2, as necessary. In Round 2, the panel indicated their agreement to each statement using a 3-point scale (strong consensus, ≥70% of responses and median value of 3) and were shown Round 1 responses before voting. Forty-five clinicians participated in Round 1 and 41 of those (91%) participated in Round 2. Consensus was achieved on the criteria of eligibility for systemic treatment among patients with limited skin involvement as disease involvement at special or difficult to treat areas, psoriasis-induced psychological distress, uncontrolled symptoms (e.g., scaling, bleeding, pruritus, insomnia) affecting their social life, psoriatic arthritis, or failure of topical therapy. Consensus on criteria for topical failure were persistent symptoms (e.g., itchiness, pain) and plaques, poor patient satisfaction with treatment, a need to increase medication quantity or application time after treatment with two topicals for 4 weeks; or if the Psoriasis Area Severity Index score of >3 or Physician Global Assessment Score of ≥2 after 8 weeks treatment. Our Delphi panel proposes criteria to help physicians identify patients with psoriasis and limited skin involvement who would benefit from systemic therapy and suggests a definition for topical therapy 'failure' which could indicate a move to systemic treatment is warranted.
Identifiants
pubmed: 39229687
doi: 10.1111/1346-8138.17444
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Amgen
Informations de copyright
© 2024 Japanese Dermatological Association.
Références
Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370:263–271.
Greb JE, Goldminz AM, Elder JT, Lebwohl MG, Gladman DD, Wu JJ, et al. Psoriasis. Nat Rev Dis Primers. 2016;2:16082.
Griffiths CEM, van der Walt JM, ADM, Flohr C, Naldi L, Nijsten T, et al. The global state of psoriasis disease epidemiology: a workshop report. Br J Dermatol. 2017;117:e4–e7.
Parisi R, Iskandar IY, Kontopantelis E, August M, Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590.
Kubota K, Kamijima Y, Sato T, Ooba N, Koide D, Iizuka H, et al. Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database. BMJ Open. 2015;5:1–9.
Sarkar R, Chugh S, Bansal S. General measures and quality of life issues in psoriasis. Indian Dermatol Online J. 2016;7:481–488.
Bhosle KA, Kulkarni A, Feldman SR, Balkrishnan R. Quality of life in patients with psoriasis. Health Qual Life Outcomes. 2006;4:1–9.
Finlay AY, Reich K. Outcome assessment and treatment goals. Expert Rev Dermatol. 2008;3:S39–S40.
Strober B, Ryan C, van de Kerkhof P, van der Walt J, Kimball AB, Barker J, et al. Recategorization of psoriasis severity: Delphi consensus from the international psoriasis council. J Am Acad Dermatol. 2020;82:117–122.
Llamas‐Velasco M, de la Cueva P, Notario J, Martínez‐Pilar L, Martorell A, Moreno‐Ramírez D. Moderate psoriasis: a proposed definition. Actas Dermosifiliogr. 2017;108:911–917.
Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CEM, Nast A, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303:1–10.
IPC, 2020–2023. IPC Strategic Plan 2020. Available from: https://psoriasiscouncil.org/about/strategic‐plan/
Schaarschmidt ML, Schmieder A, Umar N, Terris D, Goebeler M, Goerdt S, et al. Patient preferences for psoriasis treatments: process characteristics can outweigh outcome attributes. Arch Dermatol. 2011;147:1285–1294.
Iversen L, Jakobsen HB. Patient preferences for topical psoriasis treatments are diverse and difficult to predict. Dermatol Ther (Heidelb). 2016;6:273–285.
Schmieder AS, Schaarschmidt ML, Umar N, Terris DD, Goebeler M, Goerdt S, et al. Comorbidities significantly impact patients' preferences for psoriasis treatments. J Am Acad Dermatol. 2012;67:363–372.
Feldman SR, Holmen Moeller A, Erntoft Idemyr ST, Gozalez JM. Relative importance of mode of Administration in Treatment Preferences among plaque psoriasis patients in the United States. J Health Econ Outcomes Res. 2016;4:141–157.
Martin G, Young M, Aldredge L. Recommendations for initiating systemic therapy in patients with psoriasis. J Clin Aesthet Dermatol. 2019;12:13–26.
Torii H, Kishimoto M, Tanaka M, Noguchi H, Chaudhari S. Patient perceptions of psoriatic disease in Japan: results from the Japanese subgroup of the understanding psoriatic disease leveraging insights for treatment (UPLIFT) survey. J Dermatol. 2022;39:818–828.
Richard MA, Aubin F, Beneton N, Bouloc A, Bursztejn AC, Descamps V, et al. Moderate psoriasis in clinical practice: French expert consensus using a modified Delphi method. Adv Ther. 2022;39:5203–5215.
Okoli C, Pawlowski SD. The Delphi method as a research tool: an example, design considerations and applications. Inf Manag. 2004;42:15–29.
Santaguida P, Dolovich L, Oliver D, Lamarche L, Gilsing A, Griffith LE, et al. Protocol for a Delphi consensus exercise to identify a core set of criteria for selecting health related outcome measures (HROM) to be used in primary health car. BMC Fam Pract. 2018;19:1–14.
De Meyer D, Kottner J, Beele H, Schmitt J, Lange T, van Heck A, et al. Delphi procedure in core outcome set development: rating scale and consensus criteria determined outcome selection. J Clin Epidemiol. 2019;111:23–31.
Boulkedid R, Abdoul H, Loustau M, Sibony O, Alberti C. Using and reporting the Delphi method for selecting healthcare quality indicators: a systematic review. PLoS One. 2011;6:e20476.
Goto Y, Miura H. Challenges in promoting shared decision‐making: towards a breakthrough in Japan. Evid Fortbild Qual Gesundhwes. 2022;171:84–88.
Charles C, Gafni A, Welan T. Decision‐making in the physician‐patient encounter: revisiting the shared treatment decision‐making model. Soc Sci Med. 1999;49:651–661.
Gibson A, Cooper M, Rae J, Hayes J. Clients' experiences of shared decision making in an intergative psychotherapy for depression. J Eval Clin Pract. 2019;26(2):559‐568.
Amatore F, Villani AP, Tauber M, Viguier M, Guillot B. French guidelines on the use of systemic treatments for moderate‐to‐severe psoriasis in adults. J Eur Acad Dermatol Venereol. 2019;33:464–483.
Okubo Y, Tsuruta D, Tang AC, Inoue S, Torisu‐Itkara H, Hanada T, et al. Analysis of treatment goal alignment between Japanese psoriasis patients and their paired treating physicians. J Eur Acad Dermatol Venereol. 2018;32:606–614.
Okubo Y, Torisu‐Itakura H, Hanada T, Aranishi T, Inoue S, Ohtsuki M. Evaluation of treatment satisfaction misalignment between Japanese psoriasis patients and their physicians. Curr Med Res Opin. 2021;37:1103–1109.
Okubo Y, Arai K, Fujiwara S, Amaya M, Tsuboi R. Assessment of the quality of life of patients with psoriasis using skindex‐16 and GHQ‐28. Jpn J Dermatol. 2007;117:2495–2505.
Nakagawa H, Igarashi A, Etoh T, Ozawa A, Nemoto O. The results of a psoriasis patients' satisfaction survey (second report): analysis of factors contributing to overall satisfaction. Jpn J Dermatol. 2005;115:1449–1459.